IHS Chemical Week

Chemical Week Magazine :: Business & Finance :: United States/Americas

GSK to license Codexis technology

4:53 PM MDT | July 21, 2014 | —Rebecca Coons

Biocatalyst firm Codexis (Redwood City, CA) and GlaxoSmithKline (GSK) have announced a technology license agreement worth up to $25 million in initial payments and milestone and royalty opportunities to Codexis. Under the terms of the deal, Codexis licenses GSK to use Codexis’s proprietary CodeEvolver protein engineering platform technology in human health care. The agreement allows GSK to use the technology to develop novel enzymes for manufacturing GSK’s pharmaceutical and health-care products. Upon completion of technology transfer, GSK will have...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa